Form 4: Zimmer Biomet Director Robert Hagemann Reports Stock Transactions

Director Robert Hagemann of Zimmer Biomet Holdings, Inc. reported transactions involving phantom stock units and restricted stock units.

Summary

• Robert Hagemann, a Director at Zimmer Biomet Holdings, Inc., has filed a Form 4 detailing transactions related to his beneficial ownership of company securities.
• The transactions involve phantom stock units and restricted stock units, which are forms of equity compensation.
• These units are to be settled in shares of the company's common stock.
• The filing indicates a total of 875.35 phantom stock units and 1,517.274 restricted stock units were acquired.
• These securities are subject to specific settlement and deferral periods based on the company's compensation plans for non-employee directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents routine reporting of director equity compensation and does not indicate significant changes in beneficial ownership or company performance.

Positives

• Director Hagemann's continued investment and reporting of equity holdings demonstrate ongoing commitment to the company.
• The acquisition of phantom stock units and restricted stock units suggests a compensation structure that aligns director interests with shareholder value.
• The immediate vesting of restricted stock units, though subject to deferral, indicates a reward for service.

Negatives

• The filing does not detail any sales of securities, which could indicate a lack of liquidity or a long-term holding strategy.
• The specific deferral periods for restricted stock units mean that the actual shares may not be available to the director for a significant period.

Risks

• The value of the phantom stock units and restricted stock units is directly tied to the performance of Zimmer Biomet's common stock, exposing the director to market risk.
• Changes in the company's stock price could impact the ultimate value received by the director upon settlement or vesting.
• The mandatory deferral of restricted stock units until termination of service or a specific date three years after grant means the director cannot immediately realize gains from these awards.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions related to director compensation.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for directors and officers of publicly traded companies, providing transparency into their holdings and transactions. The use of phantom stock units and restricted stock units is common in the medical device industry to attract and retain executive and director talent by aligning their interests with long-term company performance.

Comparison to Industry Standards

• The structure of compensation involving phantom stock units and restricted stock units is a widely adopted practice among large-cap medical device companies like Medtronic, Abbott Laboratories, and Boston Scientific.
• These instruments are typically used to incentivize long-term performance and retention, with vesting and settlement schedules often tied to continued service and company stock performance, mirroring the terms described for Zimmer Biomet's director.

Related Party Transactions

• The transactions reported involve equity awards granted under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, which are standard compensation arrangements between the company and its directors.

Stakeholder Impact

• Shareholders: Increased transparency into director holdings and compensation structures.
• Employees: The compensation structure for directors may influence overall compensation philosophy within the company.
• Management: Reinforces alignment of director interests with company performance.

Next Steps

• Settlement of phantom stock units in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
• Mandatory deferral of restricted stock units until the later of the reporting person's termination of service as a Director or three years after the grant date.

Key Dates

Keywords

Zimmer Biomet Holdings, Form 4, Robert Hagemann, Director, Phantom Stock Units, Restricted Stock Units, Beneficial Ownership, SEC Filing, Equity Compensation